| | Schriftenverzeichnis 1. R.Appel und M.Montenarh. Notiz über ein neues Verfahren zur Darstellung von Organylsulfonylisocyanaten. Chem. Ber. 107, 706-709 (1974). 2. R.Appel, H.Uhlenhaut und M.Montenarh. Cyclisierungsreaktion zwischen Chlorsulfonylisocyanat und Bis(trimethylsilylimido)schwefeloxid. Z. Naturforsch. 29B, 799 (1974). 3. R.Appel und M.Montenarh. Reaktionen von N,N-Dialkyl- und N,N,-Diarylsulfamiden mit Chlorsulfonylisocyanat. Chem. Ber. 108, 618-622 (1975). 4. R.Appel, M.Montenarh und I.Ruppert. Über die Cycloaddition von Sulfonylisocyanaten mit Tetraschwefeltetranitrid. Chem. Ber. 108, 582-588 (1975). 5. R.Appel und M.Montenarh. Silylierungsreaktionen an Amidoschwefelsäurederivaten. Chem. Ber. 108, 1442-1446 (1975). 6. R.Appel und M.Montenarh. Darstellung und Reaktionen silylierter Amidoschwefelsäurederivate mit Schwefel(IV)-halogeniden. Chem. Ber. 108, 2340-2348 (1975). 7. R.Appel und M.Montenarh. Reaktionen mit monosilylierten Schwefel- und Carbodiimiden. Z. Naturforsch. 30B, 847-849 (1975). 8. R.Appel und M.Montenarh. Reaktionen von Sulfonylisocyanaten mit Schwefeldiimiden. Chem. Ber. 109, 2437-2441 (1976). 9. R.Appel, I.Ruppert und M.Montenarh. Schwefeltrioxid-Einschiebung an silylierten Iminophosphoranen. Chem. Ber. 109, 71-75 (1976). 10. M.Montenarh und R.Appel. Kondensationsreaktionen von silylierten Sulfamiden mit Trithiadiazyldichlorid. Z. Naturforsch. 31B, 902-904 (1976). 11. R.Appel und M.Montenarh. Darstellung sulfamoylsubstituierter Silazane. Z. Naturforsch. 31B, 993-994 (1976). 12. R.Appel und M.Montenarh. Additionsreaktionen von N,N-Dialkylsulfamiden, tertiären Aminen und Phosphinen mit Fluorsulfonylisocyanat. Chem. Ber. 110, 2368-2373 (1977). 13. R.Appel und M.Montenarh. Spiro-bis-(1,1-dioxo-2,4-bis(trimethylsilyl)-1d6 2,4,2-thiadiazasiletidin), ein neues Spirosilazan. Z. Naturforsch. 32B, 108 (1977). 14. R.Appel und M.Montenarh. Reaktionen von silylierten Amidoschwefelsäuren und Sulfonamiden mit Schwefelchloriden. Chem. Ber. 111, 759-763 (1978). 15. M.Montenarh und R.Henning. Simian Virus 40 T-antigen phosphorylation is variable. FEBS Letters 114, 107-110 (1980). 16. M.Montenarh und R.Henning. Influence of the phosphorylation of simian virus 40 T-antigen on its binding to DNA and phosphocellulose. Biochem. Soc. Trans. 9, 234 (1981). 17. M.Montenarh und R.Henning. The binding of simian virus 40 large T antigen to the polyphosphate backbone of nucleic acids. Biochim. Biophys. acta 697, 322-329 (1982). 18. M.Montenarh, W.Deppert und R.Henning. Mapping of a DNA-binding domain of simian virus 40 T-antigen using non-defective adenovirus 2-simian virus 40 hybrid viruses. FEBS Letters 142, 129-132 (1982). 19. M.Montenarh und R.Henning. Disaggregation and reconsti-tution of oligomeric complexes of simian virus 40 large T-antigen. J. Gen. Virol. 64, 241-246 (1983). 20. M.Montenarh und R.Henning. Self-assembly of simian virus 40 large T antigen oligomers by divalent cations. J. Virol. 45, 531-538 (1983). 21. M.Montenarh, M.Kohler und R.Henning. Oligomerization of simian virus 40 large T antigen is not necessarily repressed by temperature-sensitive A gene lesions. J. Virol. 49, 658-664 (1984). 22. H.W.Stürzbecher, M.Mörike, M.Montenarh und R.Henning. Relationship of the phosphorylation to the oligomerization of SV40 T antigen and its association with p53. FEBS Letters 180, 285-290 (1985). 23. C.Schürmann, M.Montenarh, M.Kohler und R.Henning. Oligomerization of simian virus 40 (SV40) tumor antigen may be involved in viral DNA-replication. Virology 146, 1-11 (1985). 24. M.Montenarh, M.Kohler, G.Aggeler und R.Henning. Structural prerequisites of simian virus 40 large T antigen for the maintenance of cell transformation. EMBO J. 4, 2941-2947 (1985). 25. M.Montenarh, C.Vesco, G.Kemmerling, D.Müller und R.Henning. Regions of SV40 large T antigen necessary for oligomerization and complex formation with the cellular oncoprotein p53. FEBS Letters 204, 51-55 (1986). 26. M.Montenarh, M.Kohler und R.Henning. Complex formation of simian virus 40 large T antigen with cellular protein p53. J. Virol. 60, 761-764 (1986). 27. M.Montenarh, C.Vesco, und K.-H.Scheidtmann. Dimers and complexes with p53 constitute the oligomeric forms of a transforming non-karyophilic T antigen of simian virus 40. J. Virol. 61, 940-944 (1987). 28. M.Montenarh und D.Müller. Properties of SV40 T antigen from two point mutants affecting the phophorylation of T antigen. J. Cancer Res. Clin. Oncol. 113, 34 (1987). 29. H.-W.Stürzbecher, M.Montenarh und R.Henning. Enhanced protein phosphorylation in SV40-transformed and infected cells. Virology 160, 445-455 (1987). 30. D.Müller, I.Ugi, K.Ballas, P.Reiser, R.Henning und M.Montenarh. The AT-rich sequence of the SV40 control region influences the binding of SV40 T antigen to binding sites II and III. Virology 161, 81-90 (1987). 31. M.Montenarh und D.Müller. The phosphorylation at Thr 124 of simian virus 40 large T antigen is crucial for its oligomerization.FEBS Lett. 221, 199-204 (1987). 32. G.Stetter, D.Müller und M.Montenarh. SV40 T antigen binding to site II functionally separated from binding to site I. Virology 164, 309-317 (1988). 33. M.Mörike, A.Quaiser, D.Müller und M.Montenarh. Stimulation of quiescent NIH3T3 cells by serum or purified simian virus 40. Oncogene 3, 151-158 (1988). 34. S.Kraiss, A.Quaiser, M.Oren und M.Montenarh. Oligomerization of the oncoprotein p53. J. Virol. 62, 4737-4744 (1988). 35. M.Montenarh und A.Quaiser. Two different protein-protein interactions in oligomeric complexes of SV40 large T antigen with the cellular oncoprotein p53. Oncogene 4, 379-382 (1989). 36. G.Stetter und M.Montenarh. Complex interaction of SV40 large T antigen with the control region on the SV40 DNA. Oncogene 4, 1353-1357 (1989). 37. E.Reihsaus, M.Kohler, S.Kraiss, M.Oren und M.Montenarh. Regulation of the level of the oncoprotein p53 in non- transformed and transformed cells. Oncogene 5, 137- 145 1990. 38. C.Buck und M.Montenarh Platelet derived growth factor (PDGF) Immun. Infekt. 18, 132- 135 (1990). 39. S.Kraiss, A.Barnekow und M.Montenarh. Protein kinase activity associated with immunopurified p53 protein. Oncogene 5, 845- 855 (1990). 40. S.Kraiss, R.Espig, U.Vetter, W.Hartmann und M.Montenarh. Expression of p53 in human leukemic cell lines. Leukemia Res. 14, 1041- 1051 (1990). 41. S.Kraiss, S.Spieß, E.Reihsaus und M.Montenarh. Correlation between metabolic stabilization and altered quaternary structure of oncoprotein p53. Exp. cell Res. 192, 157- 164 (1991). 42. G.Stetter, M.A.Braun und M.Montenarh. A new DNA binding assay to study subclasses of SV40 large T antigen binding to individual binding sites on the SV40 DNA. Oncogene 6, 389 -396 (1991). 43. G.Stetter und M.Montenarh. Binding of subclasses of SV40 T antigen to separate binding regions of the SV40 DNA. Virol. (Life Sci. Adv.) 10, 29-41 (1991). 44. H.Seliger, A.Fröhlich, M.Montenarh, J.F.Ramalho Ortigao und H.Rösch. Oligonucleotide analogues with 3`-3` and 5`-5` internucleotide linkages as antisense inhibitors of viral replication. Nucleosides, Nucleotides 10, 469- 477 (1991) 45. C.P.E.Herrmann, S.Kraiss und M.Montenarh. Casein kinase II is tightly associated with immunopurified p53. Oncogene 6, 877- 884 (1991). 46. P.Schmid, A.Lorenz, H.Hameister und M.Montenarh. Expression of p53 during mouse embryogenesis. Development 113, 857- 865 (1991). 47. H.Seliger, A.Fröhlich, G.Gröger, B.Krist, M.Montenarh, H.Rösch, R.Rösch und F.Ramalho Ortigao. Synthetic oligonucleotides for biomedical applications. Nucl.Acid.Res.Sym.Ser. 24, 193- 196 (1991). 48. S.Kraiss, A.Lorenz und M.Montenarh. Protein-protein interactions in high molecular weight forms of the transformation-related phosphoprotein p53. Biochim.Biophys. Acta 1119, 11- 18 (1992). 49. E.Reihsaus, S.Kraiss, A.Barnekow und M.Montenarh. Cooperation of p53 and polyoma virus middle T antigen in the transformation of primary rat embryo fibroblasts. Exp. Cell Res. 199, 10-18 (1992). 50. J.F. Ramalho Ortigao, H.Rösch, H.Selter, A.Lorenz, M.Montenarh und H.Seliger. Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: A minimal modification protecting against nucleolytic degradation. Antisense Res. Dev. 2: 129- 146 (1992). 51.M.Montenarh. Biochemical, immunological, and functional aspects of the growth-suppressor/ oncoprotein p53, p. 233-256. In Critical Reviews in Oncogenesis. Vol. 3. CRC Press, Inc., 52. A.Lorenz, C.P.E.Herrmann O.-G.Issinger und M.Montenarh. Phosphorylation of wild-type and mutant phenotypes of p53 by an associated protein kinase. Int. J. Oncol. 1: 571- 579 (1992) 53. M.Montenarh. Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 7, 1673- 1680 (1992). 54. M.Montenarh. Functional implications of the growth suppressor/oncoprotein p53. Int. J. Oncol. 1, 37- 45 (1992) 55. G.V.Lopashov, H.Selter, M.Montenarh, W.Knöchel, H.Grunz, H.Tiedemann und H.Tiedemann. Neural inducing factors in neuroblastoma and retinoblastoma cell lines. Naturwissenschaften 79, 365- 367 (1992). 56. H.Selter und M.Montenarh. Properties of a C-terminal polypeptide fragment of simian virus 40 large T antigen. Int. J. Oncol. 2, 837- 845 (1993) 57. P.Lang, E.-D.Kreuser, J.Maurer, D.Höher, G.Bornhöft, M.Montenarh und E. Thiel. Mutation and expression of p53 tumor samples and cancer cell lines: Comparison of non-isotopic direct DNA- sequencing, immunoblotting and immunohistochemistry. Int. J. Oncol. 2, 347- 355 (1993) 58. M.Hoever, J.H.Clement, D. Wedlich, M.Montenarh und W.Knöchel. Overexpression of wild-type p53 interferes with normal development inXenopus laevisembryos. Oncogene 9, 109- 120 (1994) 59. D. Höher, S.Kartarius, F.Porzsolt und M.Montenarh. Immunologically defined subclasses of the growth suppressor protein p53 detected with antibodies in sera from tumor patients. Int. J. Oncol. 3, 741- 747 (1993) 60. H. Selter und M.Montenarh, The emerging picture of p53. Int. J. Biochem. 26, 145- 154 (1994) 61. P.Wagner, K.Appel, O.-G-Issinger und M.Montenarh, On the interaction of p53 with casein kinase II. Int. J. Oncol. 4, 491- 498 (1994) 62. M.Montenarh, C.P.E.Herrmann, D.Höher und H.Selter. Biochemical properties of p53 in a human tumor cell line. Cancer Mol. Biol. 1, 121- 131 (1994) 63. K.Appel, E.Schneider, P.Wagner and M.Montenarh, A new 42 KDa protein binding to the growth suppressor protein p53. Int. J. Oncol. 5, 667- 673, (1994) 64. D.Sturm and M.Montenarh, Expression of p53 after SV40 virus infection of quiescent cells. Int. J. Oncol. 5, 337-344, (1994) 65. U.Burk, H.Selter, Th.Zwergel, B.Wullich, M.Montenarh und G.Unteregger. Different subnuclear localization of wild-type and mutant p53 in human prostate cancer cells. Int. J. Oncol. 7, 1355- 1360 (1995) 66. F.Porzsolt, M.Schmid, D.Höher, R.Muche, W.Gaus und M.Montenarh Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie, 17, 402- 408, (1994) 67. P.Wagner, M.Hoever, K.Appel, W.Knöchel, und M.Montenarh. Fission yeast tms1 protein abrogates normal development inXenopus laevisembryos. Roux`s Archive Dev. Biol. 204, 198- 202 (1995) 68. D.Sturm und M.Montenarh. Early response of quiescent cells to SV40 virus infection. Int. J. Oncol. 5, 1411- 1418 (1994). 69. P.Wagner, C.Waschow, W.Nastainzcyk und M.Montenarh, New monoclonal antibodies against the tumor mutant suppressor tms1. Hybridoma 13, 527- 529 (1994). 70. M.Montenarh. Marker genes for cytotoxic exposure:p53. Stem Cells 13, 136- 141 (1995). 71. E.Schneider, A.Fuchs, W.Nastainczyk, M.Montenarh und P.Wagner. Precise epitope mapping of three monoclonal antibodies raised against tms1 protein of fission yeast. Hybridoma 14, 329- 333 (1995). 72. C.Götz und M.Montenarh. p53: DNA damage, DNA repair and apoptosis. Rev. Physiol. Biochem. Pharm. 127, 65-95 (1995) 73. C.Götz, M.Koenig, O.-G.Issinger und M.Montenarh. A protein kinase CK2 related kinase is tightly associated with SV40 large T antigen. Eur. J. Biochem. 233, 327-334 (1995) 74. H.Selter, S.Amela-Neuschwander, C.Villena-Heinsen und M. Montenarh. Antibodies against mdm2 in sera of patients with various gynaecological diseases. Cancer Lett. 96, 111- 115 (1995) 75. C.Götz und M.Montenarh. p53 and its implication in apoptosis. Int.J.Oncol. 6, 1129- 1135. (1995) 76. K.Appel, P.Wagner, B.Boldyreff, O.-G.Issinger und M.Montenarh. Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory ß-subunit of protein kinase CK2. Oncogene 11, 1971- 1978 (1995) 77. P.Wagner, A.Fuchs, A.Prowald, M.Montenarh und W.Nastainczyk. Precise mapping of the tms1 binding site on p53. FEBS Lett. 377, 155- 158 (1995) 78. C.Götz, P.Wagner, O.-G.Issinger und M.Montenarh p21WAF1/CIP1 interacts with protein kinase CK2.Oncogene 13, 391- 398 (1996) 79. M.G.Koenig, D.Sturm, O.-G.Issinger, und M.Montenarh. Interaction of p53 with protein kinase CK2 during SV40 induced entrance of quiescent cells into the cell cycle. Int. J. Oncol. 10, 405-411 (1997) 80. M.Hoever, C.P.E.Herrmann und M.Montenarh. Biochemical properties ofXenopus laevisp53. Int. J. Oncol. 10, 195- 203 (1997) 81. B.Guerra, C.Götz, Wagner,P., M.Montenarh und O.-G.Issinger. The carboxy terminus of p53 mimicks the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. Oncogene 14, 2683- 2688 (1997) 82. A.Prowald, N.Schuster und M.Montenarh. Regulation of the DNA binding activity of p53 by its interaction with protein kinase CK2. FEBS Lett. 408, 99- 104 (1997) 83. A.Nickels, M.Bureik, M.Montenarh, M.Pfreundschuh und B.Koch. p53 antibodies: a call for quality. Int. J. Cancer 73, 613- 614 (1997) 84. A.Nickels, H.Selter, M.Montenarh, M. Pfreundschuh und B.Koch. Detection of p53 in inflammatory tissue and in lymphocytes by immunohistology and flow cytometry- a critical comment. J. Clinical Pathol. 50, 654- 660 (1997) 85. M.Montenarh. Das Wachstumssuppressorprotein p53, seine zellulären Partner und das Prostatacarcinom.Akt. Urol. 28, 371- 376 (1997). 86. M.Montenarh und C.Götz. p53 autoantibodies and human malignancy. Cancer Molec.Biol. 4, 991- 1010 (1997) 87. M.Montenarh und C.Götz. p53 Autoantikörper in der Tumordiagnostik.Münch. med. Wschr. 139, 673- 674 (1997) 88. P.Wagner, A.Fuchs, W.Nastainczyk, C. Götz und M.Montenarh. Fine mapping and regulation of the association of p53 and p34cdc2. Oncogene 16, 105-111 (1998) 89.N.Rief, C.Waschow, W.Nastainczyk, M.Montenarh und C.Götz. Production and characterization of a rabbit monoclonal antibody against human CDC25C phosphatase.Hybridoma 17: 389-394 (1998) 90. C.Götz, S.Kartarius, P.Scholtes und M.Montenarh.In vitrostudies of the interaction between protein kinase CK2 and p21WAF1/CIP1. Cancer Molec. Biol. 5, 1189- 1205 (1998) 91. C.Lang, G.Unteregger, S.Kartarius, J.Günther, H.Bonkhoff, M.Montenarh und T.Zwergel. p53 autoantibodies in patients with urological tumors. Br. J. Urol. 82, 721- 725 (1998) 92.M.Montenarh. Humoral response against p53 in human malignancies. In Pathogenic and diagnostic relevance of autoantibodies. Ed. K. Conrad, R.-L. Humbel, M. Meurer, Y. Shoenfeld und E. M. Tan. Pabst Science Publishers, Lengerich, Berlin, Düsseldorf 377- 394 (1998) 93. R.Hallak, J.Mueller, O.Lotter, S.Gansauge, F.Gansauge, M.E.-D.Jumma, M.Montenarh, F.Safi und H.Beger. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study. Int. J. Oncol. 12, 785- 791 (1998) 94. M.Montenarh, A.Harlozinska, J.K. Bar, S. Kartarius, J. Günther und P.Sedlaczek. p53 autoantibodies in the sera and ascites fluids with ovarian cancer. Int. J. Oncol. 13, 605- 610 (1998) 95. E.Schneider, M.Montenarh und P.Wagner. Regulation of CAK kinase activity by p53. Oncogene 17, 2733- 2742 (1998) 96. H.Selter, G.Schmidt, C.Villena-Heinsen und M.Montenarh. Humoral immune response to p21WAF1/CIP1 in tumor patients, non-tumorous patients and healthy blood donors.Cancer Lett. 137, 151- 157 (1999) 97.J.Benninghoff, Z.Teleb, H.Selter, G.Unteregger, T.Zwergel, B.Wullich und M.Montenarh. Two different forms of p53 localized differently within cells of urogenithial tumors.Cancer Letters 144, 55-64 (1999) 98. C.Götz, P.Scholtes, N.Schuster, A.Prowald, W.Nastainczyk und M.Montenarh. Protein kinase CK2 binds to a multi-protein binding domain of the growth suppressor protein p53. Mol. Cell. Biochem. 191, 111- 120 (1999) 99.N.Schuster, A.Prowald, E.Schneider, K.-H.Scheidtmann und M.Montenarh. Regulation of p53 mediated transactivation by the ß- subunit of protein kinase CK2. FEBS Letters 447, 160- 166 (1999) 100. C.Götz, S.Kartarius, P.Scholtes, W.Nastainczyk, und M.Montenarh. Identification of a CK2 phosphorylation site in mdm2.Eur. J. Biochem. 266, 493- 501 (1999) 101. M.Faust, N.Schuster und M.Montenarh. Specific binding of protein kinase CK2 catalytic subunits to tubulin. FEBS Letters 462, 51-56 (1999) 102. M.Montenarh. Humoral immune response against the growth suppressor p53 in human malignancies. In: Cancer and Autoimmunity. 193- 203 Eds: Y.Schoenfeld and M. E. Gershwin, Elsevier Amsterdam, (2000) 103. C.Götz, S. Kartarius, P. Scholtes und M.Montenarh. Binding domain for 21WAF1/CIP1 on the polypeptide chain of the protein kinase CK2 beta- subunit. Biochem. Biophys. Res. Commun. 268, 882- 885 (2000) 104. A.Harlozinska, J.Bar und M.Montenarh. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and mdm2 protein expression in ovarian carcinomas. Anticancer Res. 20(2A):1049-56 (2000) 105. U.Mack,D.Ukena,M.Montenarh und G.Sybrecht. Serum anti p53 antibodies in patiens with lung cancer. Oncology Rep. 7, 669- 974, (2000) 106. M.Montenarh. p53 Autoantikörper in der klinischen Diagnostik. Deutsche Medizinische Wochenschrift 125, 941- 943 (2000) 107. N.Rief, H.Herges, A.Prowald, C.Götz und M.Montenarh. Binding of the growth suppressor p53 protein to the cell cycle regulator phosphatase cdc25C. Int.J.Oncol. 17, 186- 195 (2000) 108. M.Faust und M.Montenarh. Subcellular localization of protein kinase CK2: A key to its function? Cell Tissue Res. 301, 329- 340 (2000) 109. M.Bureik, N.Rief, R.Drescher, A.Jungbluth, M. Montenarh und P.Wagner. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. Int. J. Oncol. 17, 1251- 1258, (2000) 110. N.Schuster, C.Götz, M.Faust, E.Schneider, A.Prowald, A. Jungbluth und M. Montenarh. Wild- type p53 inhibits protein kinase CK2 activity. J. Cell. Biochem. 81, 172- 183 (2001), 111. M.Ababneh, C.Götz und M.Montenarh. Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34cdc2. Biochemical and Biophysical Research Communications 283, 507?512 (2001) 112. M.Faust, M.Jung, J.Günther, R.Zimmermann und M.Montenarh. Localization of individual subunits of protein kinase CK2 to the endoplasmic reticulum and to the Golgi apparatus. Mol. Cell. Biochem. 227, 73- 80 (2001) 113. S.L.Schwindling, M.Faust, M.Montenarh. Determination of the mitotic index by microinjection of fluorescently labelled tubulin. Eur. J. Cell Biol. 81, 169- 174 (2002) 114. A.Harlozinska, J.K.Bar, M.Montenarh und S.Kartarius. Relations between immunologically different p53 forms, p21WAF1 and PCNA expression in ovarian carcinomas. Oncology Rep. 9 1173- 1180 (2002) 115. E.Schneider, S.Kartarius, N.Schuster und M. Montenarh. The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H. Oncogene 21, 5031-5037 (2002) 116. M.Faust, S.Kartarius, S.L.Schwindling und M.Montenarh. Cyclin H is a new binding partner for protein kinase CK2. Biochem. Biophys. Res. Commun. 296, 6- 12 (2002) 117. J.Bar, A.Harlozinska, S.Kartarius, M.Montenarh, E.Wyrodek, J.M.R.Parkitna, M.Kochman, A.Ozyhar. Temperature-sensitive ovarian carcinoma cell line (OvBH-1). Jap.J.Cancer Res. 93, 976-985 (2002) 118. M.Faust, J.Günther, E. Morgenstern, M. Montenarh und C. Götz. Specific localization of the catalytic subunits of protein kinase CK2 at the centrosomes. Cell. Mol. Life Sci. 59, 2155- 2164 (2002) 119. J.Saleh und M.Montenarh. p53 autoantibodies in the sera of paptients with various types of malignancies. Arab J. Pharmaceutical Sciences 2, 63-72 (2003) 120. M.Montenarh. Protein kinase CK2: in search for its regulation. Advances in Clinical and Experimental Medicine 12, 15- 22 (2003) 121. A.Hessenauer, M.Montenarh und C.Götz. Inhibition of CK2 activity provokes different responses in hormone- sensitive and hormone-refractory prostate cancer cells. Int. J. Oncol. 22, 1263- 1270 (2003) 122. S.Facchin, R.Lopreiato,M.Ruzzene, O.Marin, C.Götz, G.Sartori, M.Montenarh, G.Carignani, und L.A.Pinna. Functional conservation within a primordal protein kinase family:yeast piD/Bud32 and human PRPK display interchangeable roles. FEBS Letters 549, 63- 66 (2003) 123. M.Montenarh. Prognostische Bedeutung immunhistochemischer Untersuchungen. HNO 51, 787- 789 (2003) 124. S.L.Schwindling, A.Noll, M.Montenarh und C.Götz. Mutation of the CK2 phosphorylation site in cdc25C impairs importin a/b binding and results incytoplasmic retention. Oncogene 23, 4155- 4165 (2004) 125. A.Ibrahim, J.Saleh, M.Montenarh, M.Juma und M.Obeid. Serum anti-p53 antibodies in patients with atherosclerosis. Arab J. Pharmaceutical Sciences 2, 63- 68 (2004) 126. J.Saleh, D. Kreissler-Haag und M. Montenarh. p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- and C- terminus of p53. Int. J. Oncol. 25, 1149- 1156(2004) 127. B.Schick, B. Veldung, S. Wemmert, V. Jung, M. Montenarh, E. Meese, und S. Urbschat. p53 and Her-2/neu in juvenile angiofibromas. Oncology Reports 13, 453- 458 (2005) 128. C.Götz, S.Kartarius, G.Schwär und M.Montenarh. Phosphorylation of mdm2 at serine 269 impairs its interaction with the retinoblastoma protein.Int. J. Oncol. 26, 801- 808 (2005) 129. M.Bureik, A.Zöllner, N.Schuster, M.Montenarh und R.Bernhardt. Phosphorylation of bovine adrenodoxin by protein kinase CK2 affects the interaction with the redox partner cytochrome P450 scc (CYP11A1). Biochemistry 44, 3821-3830 (2005) 130. Götz,C., Kartarius,S., Schetting,S. und Montenarh,M. Immunologically defined subclasses of the protein kinase CK2ß-subunit in prostate carcinoma cell lines.Mol. Cell. Biochem. 274: 181-187, (2005). 131. Klein,A., Jung,V., Zang,K.D., Henn,W., Montenarh,M., Kartarius,S. und Urbschat,S. Detailed chromosomal characterization of the breast cancer cell line MCF7 with special focus on the expression of the serine-threonine kinase 15.Oncol. Rep. 14: 23-31, (2005). 132. Krempler,A., Kartarius,S., Günther,J. und Montenarh,M. Cyclin H is targeted to the nucleus by C-terminal nuclear localization sequences. Cell. Mol. Life Sci. 62: 1379-1387, (2005). 133. Montenarh M. in: p53 autoantibodies in the diagnosis and prognosis of tumors. p. 92-107. Conrad K, Bachmann M, Lehmann W, Sack U, editors.Methods, possibilities and perspectives in pre-symptomatic tumor diagnosis. Lengerich,Berlin,Bremen,Miami,Riga,Viernheim,Wien,Zagreb: Pabst Science Publishers, (2005). 134. Schlade-Bartusiak,K., Sasiadek,M.M., Bar,J.K., Urbschat,S., Blin,N., Montenarh,M. und Harlozinska-Szmyrka,A. Cytogenetic and molecular cytogenetic characterisation of the stable ovarian carcinoma cell line (OvBH-1). Cancer Genet. Cytogenet. 164:10-15, (2006). 135. Saleh,J., Brunner,C., Gölzer,R., Nastainczyk,W. und Montenarh,M. p53autoantibodies from patients with head and neck cancer recognize common epitopes on the polypeptide chain of p53. Cancer Lett. 233: 48-56, (2006). 136. Schick,B., Wemmert,S., Jung,V., Steudel,W.I., Montenarh,M. und Urbschat,S. Genetic heteregeneity of the MYC oncogene in advanced juvenile angiofibromas. Cancer Genet. Cytogenet. 164: 25-31, (2006). 137. Bachmann,M., Kosan,C., Xiang,P.X., Montenarh,M., Hoffmann,I. und Möröy,T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates G2/M specific phosphatase Cdc25C. Int. J. Biochem. Cell Biol. 38 (3): 430-443, (2006). 138. Kramerov, A.A., Saghizadeh,M, Pan,H., Kabosova,A., Montenarh,M., Ahemd,K., Penn,J.S., Chan,C.K., Hinton,D.R., Grant,M.B. und Ljubimov, A.V., Expression of Protein kinase CK2 in Astrtoglial Cells of normal an neovascularized Retina, Am. J. Pathol.168(5), 1722-1736, (2006) 139. Touma, R., Kartarius, S., Harlozinska, A. Götz, C. und Montenarh, M. Growth inhibition and apoptosis induction in ovarian cancer cells. Int. J. Oncol. 29 , 481- 488 (2006) 140. Noll,A., Ruppenthal,S. und Montenarh,M. The mitotic phosphatase cdc25C at the Golgi apparatus. Biochem. Biophys. Res. Commun. 351: 825- 830 (2006) 141. Götz,C., Bachmann,C. und Montenarh,M. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependet transcription in prostate cancer cells. The Prostate 67: 125- 134 (2007) 142. Ruppenthal,S.L., Noll,A., Götz,C. und Montenarh,M. Interference between p53 and cdc25C in cell cycle regulation. Int. J. Oncol. 31, 345- 362 (2007) 143. Busch,C., Barton,O., Morgenstern,E., Günther,J., Noll,A., Götz,C. und Montenarh,M. Protein phosphatase cdc25C is located within centrosomes. Int. J. Biochem.Cell Biol. 39, 1707- 1713 (2007) 144. Prowald,A., Cronauer,M.V., von Klot,C., Eilers,T.,Rinnab,L., Herrmann,T, Spindler,K.D., Montenarh,M.,Jonas,U., Burchardt,M. Modulation ofβ-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.The Prostate 67, 1751- 1760 (2007) 145. Lehnert,S., Götz,C., Kartarius,S., Schäfer,B. und Montenarh,M. Protein kinase CK2 interacts with the splicing factor hPrp3p.Oncogene 27, 2390 - 2400 (2008) 146. Al-Quobaili,F. und Montenarh,M. Pancreatic duodenal homeobox factor-1 and diabetes mellitus type 2.Int. J. Mol. Medicine 21, 399- 404 (2008) 147. Touma,R. und Montenarh,M. Laboratory study of the cdc25C enzymatic activity in ovarian cancer. J.Clin.Lab.4,9- 18 (2008) 148. Dörr,J., Kartarius,S., Götz,C. und Montenarh, M. Contribution of the individual subunits of protein kinase CK2 and of hPrp3p to the splicing process. Mol. Cell. Biochem.316,187- 193 (2008) 149. Kramerov,A.A., Saghizadeh,M., Caballero,S., Shaw,L.C., Li Calzi,S., Bretner,M., Montenarh,M., Pinna,L.A., Grant,M.B. und Ljubimov,A.V. Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.Mol. Cell. Biochem.316,177- 186 (2008) 150. Schäfer,B., Götz,C. und Montenarh,M. The kinesin I family member KIF5C is a new substrate for protein kinase CK2.Biochem. Biophys. Res. Commun.375,179- 183 (2008) 151. Schäfer,B., Götz,C., Dudek, J., Hessenauer, A., Matti, U. und Montenarh, M. KIF5C: a new binding partner for protein kinase CK2 with a preference for the CK2alpha'. Cell. Mol. Life Sci. 66, 339- 349 (2009) 152. Schneider,C.C., Hessenauer,A., Götz,C. und Montenarh,M. DMAT, an inhibitor of proetin kinase CK2 induces reactive oxygen species and DNA double strand breaks. Oncology Rep. 21, 1593- 1597 (2009) 153. Cerella,C., Scherer,C., Cristofanon,S., Henry,E., Anwar,A., Busch,C., Montenarh,M., Dicato,M., Jacob,C. und Diederich,M. Cell cycle arrest in early mitosis and induction of caspase-dependent apoptosis in U937 cells by diallyltetrasulfide (Al2S4). Apoptosis. 14, 641- 647 (2009) 154. Götz,C., Müller,A., Montenarh,M., Zimmermann,R. und Dudek,J. The ER-membrane-resident Hsp40 ERj1 is a novel substrate for protein kinase CK2. Biochem. Biophys. Res. Commun. 388, 637- 642 (2009) 155. Schneider,C.C., Hessenauer,A., Montenarh,M., und Götz,C. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. The Prostate 70, 126- 134 (2010) 156. Busch, C., Jacob, C., Anwar, A., Burkholz, T., Aicha Ba, L., Cerella, C., Diederich, M., Brandt, W., Wessjohann, L. und Montenarh, M. Diallylpolysulfides induce growth arrest and apoptosis. Int. J. Oncol. 36, 743- 749 (2010) 157. Meng, R., Al-Quobaili, F., Müller, I., Götz, C., Thiel, G. und Montenarh, M. CK2 phosphorylation of Pdx-1 regulates its transcription factor activity. Cell. Mol. Life Sci. 67, 2481-2489(2010) 158. Mannowetz,N., Kartarius,S., Wennemuth,G. und Montenarh,M. Protein kinase CK2 and new binding partners during spermatogenesis. Cell. Mol. Life Sci. 67, 3905- 3913 (2010) 159. Ampofo,E., Kietzmann,T., Zimmer,A., Jakupovic,M., Montenarh,M. und Götz,C. Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. Int. J. Biochem. Cell Biol. 42, 1729- 1735 (2010) 160. Hessenauer,A., Schneider,C.C., Götz,C. und Montenarh, M. CK2 inhibition induces apoptosis via the ER stress response. Cellular Signaling 23, 145- 151 (2011) 161. Hammadeh,M.E., Hamad,M.F., Montenarh,M. und Fischer-Hammadeh,C. Protamine contents and P1/P2 ratio in human spermatozoa from smokers and non-smokers. Human Reproduction 25, 2708- 2720 (2010) 162. Meng,R., Götz,C. und Montenarh,M. The role of protein kinase CK2 in the regulation of the insulin production of pancreatic islets. Biochem. Biophys. Res. Commun. 401, 203- 206 (2010) 163. Montenarh,M Cellular regulators of protein kinase CK2. Cell and Tissue Res. 342, 139- 146 (2010) 164. Olsen,B.B., Fischer,U., Rasmussen,R.L., Montenarh,M., Meese,E., Fritz,G., Issinger,O.G. Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2alpha' levels. Mol.Cell.Biochem. 356, 139- 147 (2011) 165. Schneider,C.C., Götz,C., Hessenauer,A., Günther,J., Kartarius,S., Montenarh,M. Down-regulation of CK2 activity results in a decrease in the level of cdc25C phosphatase in different prostate cancer cell lines. Mol.Cell.Biochem. 356, 177-184 (2011) 166. Montenarh,M. Diallyl sulfides and the decision about life and death of a cell. p 329-344, in "Natural compounds as inducers of cell death: Volume I" eds. M. Diederich und K. Noworyta, Springer Science+Business Media, Dordrecht, (2012) 167. Jacob,C., Burkholz,T., Du,P., Battaglia,E., Bagrel,D. und Montenarh,M. Control of oxidative posttranslational cysteine modifications: From intricate chemistry to widespread biological and medical applications. Chem.Res.Toxicol. 25, 588- 604 (2012) 168. Montenarh,M. und Saidu,N.E.B. The effect of diallyl polysulfanes on cellular signaling cascades. Nat. Product Commun. 7, 401- 408 (2012) 169. Essa,S., Reichrath,S., Mahlknecht,U., Montenarh,M., Vogt,T. und Reichrath,J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Research 32, 383- 389 (2012) 170. Saidu,N.E.B., Valente,S.,Bana,E., Kirsch,G., Bagrel,D. und Montenarh,M. Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells. Bioorganic & Medicinal Chemistry 20, 1584- 1593 (2012) 171. Wilhelm,N., Kostelnik,K., Götz,C. und Montenarh,M. Protein kinase CK2 is implicated in early steps of the differentiation of pre- adipocytes into adipocytes. Mol. Cell. Biochem. 365, 37-45 (2012) 172. Feng,D., Welker,S., Körbel,C., Rudzitis-Auth,J., Menger,M.D., Montenarh,M. und Laschke, M. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis 15, 243-252 (2012) 173. Schneider,C.C., Ampofo,E. und Montenarh,M. CK2 regulates ATF4 and CHOP transcription within the cellular stress response signaling pathway. Cellular signaling 24, 1797- 1802 (2012) 174. Schneider,C.C., Kartarius,S., Montenarh,M. Oreszko,A. und Kazimierzcuk,Z. Modified tetrahalogenated benzimidazols with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro. Bioorganic and Medicinal Chemistry 20, 4390- (4396 (2012) 175. Al-Quobaili,F. und Montenarh,M. CK2 and the regulation of the carbohydrate metabolism. Metabolism 61, 1512-1517 (2012) 176. Montenarh,M. und Götz,C. The interactome of protein kinase CK2. pp 76- 116, in Protein Kinase CK2, Ed. Lorenzo A. Pinna, John Wiley & Sons, Inc. (2013) 177. Saidu,N.E.B., Touma,R., Abu Asali,I., Jacob,C. und Montenarh,M. Diallyl tetrasulfane activates both the eIF2α and Nrf2/HO-1 pathways. Biochim. Biophys. Acta 1830, 2214- 2225 (2013) 178. Ampofo,E., Sokolowsky,T., Götz,C. und Montenarh,M. Functional interaction of protein kinase CK2 and activating transcription factor 4 (ATF4), a key player in the cellular stress response. Biochim. Biophys. Acta Mol. Cell. Res. 1833, 439- 451 (2013) 179. Ampofo,E., Welker,S., Jung,M., Müller,L., Greiner,M., Zimmermann,R. und Montenarh,M. CK2 phosphorylation of human Sec63 regulates its interaction with Sec62. Biochim. Biophys. Acta 1830, 2938- 2945 (2013) 180. Götz,C. und Montenarh,M. Protein kinase CK2 in the ER stress response. Ad. Biol. Chem. 3, 1- 5 (2013) 181. Saidu,N.E.B., Abu Asali,I., Czepukojc,B., Seitz,B., Jacob,C. und Montenarh,M. Comparison between the effects of diallyl tetrasulfide on human retina pigment epithelial cells (ARPE-19) and HCT116 cells. Biochim. Biophys. Acta 1830, 5267- 5276 (2013) 182. Lupp,S., Gumhold,C., Ampofo,E., Montenarh,M. und Rother,K.CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2α and CK2β gene expression. Mol. Cell. Biochem. 384, 71- 82 (2013) 183. Welker,S., Götz,C.,Servas,C.,Laschke,M.W., Menger,M.D. und Montenarh,M. Glucose regulates protein kinase CK2 in pancreatic β-cells and its interaction with PDX-1. The International Journal of Biochemistry & Cell Biology 45, 2786- 2795 (2013) 184. Du,P., Viswanathan,U., Kairan,K., Buric,T., Saidu,N.E.B., Xu,Z., Hanf,B., Bazukyan,I., Trchounian,A., Hannemann,F., Bernhardt,I., Burkholz,T.,Disel,B., Kiemer,A., Schäfer,K.H., Montenarh,M., Kirsch,G., Jacob,C. Synthesis of amphiphilc,chalkogen-based redox modulators with in vitro cytotoxic activity against cancer cells, macrophages and microbes. MedChemComm 5, 25-31 (2014) 185, Cepukojc,B., Baltes,A.K., Cerella,C., Kelkel,M., Viswanathan,U.M., Salm, F., Burkholz,T., Schneider,C., Dicato,M., Montenarh,M., Jacob,C., Diederich,M. Synthetic polysulfane derivatives induce cell cycle arrest and apoptotic cell death in human hematopoietic cancer cells. Food Chem. Toxicol. 64, 249- 257 (2014) 186. Du,P., Saidu,N.E.B., Intemann,J., Jacob,C. und Montenarh,M. A new tellurium-containing amphiphilic molecule induces apoptosis in HCT116 colon cancer cells Biochim. Biophys. Acta 1840, 1808- 1816 (2014) 187. Montenarh,M. Protein kinase CK2 and angiogenesis. Advances in Clinical and Experimental Medicine 23, 153- 158 (2014) 188. Intemann,J. Saidu,N.E.B., Schwind,L. und Montenarh,M. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945. Cell Signaling 26, 1567- 1575 (2014) 189. Hamad,M., Shelko,N., Kartarius,S., Montenarh,M. und Hammadeh,M.E. Impact of cigarette smoking on histone (H2B) to protamine ratio in human spermatozoa and its relation to sperm Parameters. Andrology 2, 666- 677 (2014) 190. Welker,S., Servas,C., Meng,R. Götz,C. und Montenarh,M. Tissue specific functions and regulation of protein kinase CK2.in Protein kinase CK2 cellular function in normal and disease states. eds Ahmed,K., Issinger,O.G. und Szyszka,R. Springer 109- 123 (2015) 191. Lupp,S., Götz,C., Khadouma,S., Horbach,T., Dimova,E.Y., Bohrer, A.-M., Kietzmann,T. und Montenarh,M. The upstream stimulatory factor USF1 is regulated by protein kinase CK2 phosphorylation. Cell Signaling 26, 2809- 2817 (2014) 192. Schwind,L., Zimmer,A.D., Götz,C. und Montenarh,M. CK2 phosphorylation of C/EBPdelta regulates ist transcription factor activity. Int. J. Biochem. Cell. Biol. 61, 81- 89 (2015) 193. Schwind,L., Wilhelm,N., Kartarius,S., Montenarh,M., Gorjub,E. und Götz,C. Protein kinase CK2 is necessary for the differentiation of human mesenchymal stem cells. Biochim. Biophys. Acta 1853, 2207- 2216 (2015) 194. Rezk Allah,D., Schwind,L., Abu Asali,I., Nasim, J., Jacob,C., Götz,C. und Montenarh,M. A scent of therapy: Synthetic polysulfanes with improved physico-chemical properties induce apoptosis in human cancer cells. Int. J. Oncol. 47, 991-1000 (2015) 195. Ampofo,E., Rudzitis-Auth,J., Dahmke,I.N., Rössler,O., Thiel,G., Montenarh,M., Menger,M.D. und Laschke,M.W. Inhibition of protein kinase CK2 suppresses tumor necrosis factor (TNFalpha) nduced leukocyte-endothelial cell interaction. Biochim. Biophys. Acta Molecular Basis of Disease 1852, 2123- 2136 (2015) 196. Ampofo,E., Müller,I., Dahmke,I.N., Eichler,H., Montenarh,M., Menger,M.D. und Laschke,M. Role of protein kinase CK2 in the dynamic interaction of platelets, leukocytes and endothelial cells during thrombus formation. Thrombosis Research 136, 996- 1006 (2015) 197. Spohrer,S., Dimova, E.Y., Kietzmann,T., Montenarh,M. und Götz,C. The nuclear fraction of protein kinase CK2 binds to the upstream stimulatory factors (USFs) in the absence of DNA. Cell signalling 28, 23- 31 (2016) 198. Montenarh,M. Protein Kinase CK2 in DNA damage and repair. Translational Cancer Research 5, 49- 63 (2016) 199. Shelko,N., Hamad,M.F., Montenarh,M. und Hammadeh,M.E. The Influence of cigarette smoking on sperm Quality and sperm membrane integrity. Current Women's Health Review 12, 58- 65 (2016) 200. Ampofo,E., Widmaier,D., Montenarh,M., Menger,M. und Laschke,M. Protein kinase CK2 regulates leukocyte-endothelial cell interactions during ischemia and reperfusion. European Surgical Research 57, 111- 124 (2016) 201. Hammadeh,E.M., Amor,H. und Montenarh,M. Cigarette Smoking and structural, biochemical functional alterations of spermatozoa and their consequences for ART. Austin J In Vitro Fertil. 3, (1) 1027 (2016) 202. Faulstich,L., Griffin,S., Nasim,M.J., Masood,M.I., Ali,W., Alhamound,S., Omram,Y., Kim,H., Kharma,A., Schäfer,K.H., Lilischkis,R., Montenarh,M., Keck,C. und Jacob,C. Nature's Hat-trick:Can we use sulfur springs as ecological source for materials with agricultural and medical applications? Int. J. Biodeterioration and Biodegradation 119, 678-686 (2017) 203. Götz,C. und Montenarh,M. Protein kinase CK2 in development and differentiation Biomed. Rep. 6: 127- 133 (2017) 204. Klein,S., Meng,R. Montenarh, M. und Götz,C. The phosphorylation of PDX-1 by protein kinase CK2 is crucial for its stability. Pharmaceuticals 10, E2 (2016) 205. Schwind,L., Schetting,S. und Montenarh,M. Inhibition of protein kinase CK2 prevents adipogenic differentiation in mesenchymal stem cells like C3H10T1/2 cells. Pharmaceuticals 10, E22 (2017) 206. Jose,J., Le-Borgne, M., Pinna,L. and Montenarh, M. An updated view on an emerging target: Selected papers from the 8th International Conference on Protein Kinase CK2. Pharmaceuticals 10, E33 (2017) 207. Zwergel,C., Czepukojc,B., Evan-Bana,E., Xu,Z., Stazi,G., Mori,M., Patsilinakos,A., Mai, A., Botta,B., Ragno,R., Bagrel,D., Kirsch,G., Meiser,P., Jacob,C.,,Montenarh,M. und Valente,S. Novel coumarin- and quinolinine-based polycycles as cell Division cycle 25-A and -C phosphatases Inhibitors induce Proliferation Arrest and apoptosis in cancer cells. Eur. J. Med. Chem. 134, 316- 333 (2017) 208. Servas,C., Kiehlmeier,S., Hach,J., Gross,R., Götz,C. und Montenarh,M. The mammalian STE20-like kinase 1 (MST1) is a substrate for the apoptosis inhibiting protein kinase CK2. Cell Signalling 36, 163- 175 (2017) 209. Bender,M., Schwind,L., Grundmann,D., Klotz,M., Götz,C., Montenarh,M. und Schäfer K.H. Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells. Heliyon 2, e00318 (2017) 210. Schwind,L., Nalbach,L., Zimmer,A.D., Kostelnik,K., Menegatti,J., Grässer,F., Götz,C. und Montenarh,M. Quinalizarin inhibitis adipogenesis through down-regulation of transcription factors and microRNA modulation. Biochim. Biophys. Acta General Subjects 1861, 3272- 3281 (2017) 211. Hamad,M., Shelko,N., Montenarh,M. und Hammadeh,M.E. The Impact of cigarette Smoking on protamines 1 and 2 transcripts in human spermatozoa. Human Fertility 2017, 1-7 (2017) 212. Spohrer,S., Gross,R., Nalbach,L., Schwind,L., Stumpf,H., Menger,M.D., Ampofo,E., Montenarh,M. und Götz,C. Functional interplay between the transcription factors USF1 and PDX-1 and protein kinase CK2 in pancreatic beta cells. Sci. Rep. 7, 16367 (2017) 213. Montenarh,M. und Götz,C. Ecto-protein kinase CK2, the neclected form of CK2. Biomed. Reports 8, 307-313 (2018) 214. Hamad,M.F., Abu Dayyih,W.A., Laqqan,M., Alkaled,Y., Montenarh,M. und Hammadeh,M.E. The status of global DNA methylation in the spermatozoa of smokers and non-smokers. Reprod. Biomed. Online 37, 581-589 (2018) 215. Alshawa,E., Laqqan,M. Montenarh,M. und Hammadeh,M.E. Influence of crypreservation on the CATSPER2 and TEKT2 Expression Levels and Protein Levels in human spermatozoa. Toxicology Reports 2019, 819-824 (2019) 216. Ampofo,E., Nalbach,L.,Menger,M.D., Montenarh,M. und Götz,C. Protein kinase CK2- A putative target for the therapy of Diabetes mellitus. Int. J. Mol. Sci. 20, E4398 (2019) 217. Schmitt,B.M., Ampofo,E., Stumpf,H., Montenarh,M. und Götz,C. The stability of CREB3/Luman is regulated by protein kinase CK2 phosphorylation. Biochem. Biophys. Res. Commun. 523, 639- 644 (2020). 218. Scheuer,R., Philipp,S.E., Becker,A.,Nalbach,L.,Ampofo,E.,Montenarh,M. und Götz,C. Protein kinase CK2 controls Cav2.1-dependent calcium currents and insulin release in pancreatic beta-cells. Int. J. Mol. Sci. 21, 4668 (2020) 219. Montenarh,M. und Götz,C. Protein kinase CK2 and ion channels. Biomed. Reports 13, 55 (2020) 220. Becker,A., Götz,C.,Montenarh,M. und Philipp,S.E. Control of TRPM3 ion channels by protein kinase CK2-mediated phosphorylationin pancreatic beta-cells of the line INS-1. Int. J. Mol. Sci. 22, 13133, (2021) 221. Pack,M., Götz,C., Wrublewski,S. und Montenarh,M. SGC-CK2-1 is an efficient inducer of insulin production and secretion in pancreatic beta-cells. Pharmaceutics 14, 19 (2022). 222. Boewe,A.S., Wemmert,S., Kulas,P., Schick,B., Götz,C., Wrublewsky,S., Montenarh,M., Menger,M.D., Laschke,M.W. und Ampofo,E. Inhibition of CK2 reduces NG2 expression in juvenile angiofibroma. Biomedicines 10, 966 (2022). 223. Pack,M., Gulde,T.N., Völcker,M.V., Böwe,A.S., Wrublewsky,S., Ampofo,E., Montenarh,M. und Götz,C. Proptein kinase CK2 contributes to glucose homeostasis by targeting fructose-1,6-bisphosphatase 1. Int. J. Mol. Sci. 24, 428 (2023) 224. Montenarh,M., Grässer,F.A. and Götz,C. Protein kinase CK2 and Epstein Barr virus. Biomedicines 11, 358 (2023) 225. Montenarh,M. and Götz,C. Protein kinase CK2alpha', more than a backup of CK2alpha. Cells 12, 2834 (2023) 226. Ampofo,E., Pack,M., Wrublewsky,S., Boewe,A.S., Spigelman,A.F., Koch,H., MacDonald,P.E., Laschke M.W. Montenarh,M. und Götz,C. CK2 activity is crucial for proper glucagon expression. Diabetologia in press (2024). |
